What do systematic reviews say?

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 10 participants
  Very low

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD

Summary of findings ‐ nebulisers for delivering colistin:… may leads to lower participant satisfaction or preference compared with AAD (low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.45 [0.35, 0.57]
  1 study · 259 participants
  Low

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

It is very uncertain whether the intervention changes participant satisfaction or preference (very low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 2.33 [0.83, 6.54]
  101 participants
  Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Summary of findings ‐ nebulisers for delivering dornase alfa:… may leads to lower participant satisfaction or preference: compared with VMT (low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.48 [0.31, 0.76]
  1 study · 68 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Very low

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 8 participants
  Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes participant satisfaction or preference Satisfaction scale compared with VMT and AAD (very low certainty).

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  MD 2.7 [1.35, 4.05]
  1 study · 22 participants
  Very low